Contributions
Abstract: P760
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Background: It is known that expectations may affect response to numerous treatments. In multiple sclerosis, it has been shown to influence the adherence and ultimately the response to treatments. Our aim was to evaluate if patients" expectations regarding fampridine, assessed before initiating treatment influenced their clinical response.
Methods: We designed a prospective study from June 2015 to April 2016. We invited all consecutive patients considered for fampridine treatment in our centre to participate. Clinical data was collected and patients completed a questionnaire which included a question about fampridine information sources, a portuguese version of the Stanford Expectations of Treatment Scale (SETS) and the HADS scale to assess depression and anxiety. We analysed the effect of positive expectancy, as well as sex, age, EDSS score, and disease duration in the response at 4 weeks through a logistic regression. Chi square or Fisher analysis were used as apropriate.
Results: Out of 36 patients proposed to fampridine treatment, 32 agreed to participate in our study. 69.7% (23) were female; mean age was 52.5 years, median EDSS was 6. A benefit higher than 20% in T25FW at week 4 was observed in 72.7% (24) of patients. A high positive expectancy on SETS was the only factor associated with benefit at 4 weeks, being associated with a five-fold increase in odds of benefit at 4 weeks (OR= 5.0, 95% CI 1.01-25.57, p=0,049). Fampridine information sources, anxiety and depression scores weren"t related to SETS results.
Conclusions: In our sample, the expectations of patients seemed more relevant than sex, age, EDSS score and duration of disease in patients" response to fampridine after 4 weeks of treatment. It would be interesting to assess with bigger samples if indeed patients" expectations regarding treatment are an important factor in fampridine response.
Disclosure:
Filipa Ladeira has received travel fees from Biogen,Teva, Genzyme
Ana Sofia Correia received an educational sponsorship from Merck Serono, honorarium for advisory role from Novartis, research support and honorarium for lecturing from Biogen Idec and support for scientific meetings from Novartis, Biogen Idec, Teva and Bayer.
Miguel Viana-Baptista has no conflicts of interest
Abstract: P760
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Background: It is known that expectations may affect response to numerous treatments. In multiple sclerosis, it has been shown to influence the adherence and ultimately the response to treatments. Our aim was to evaluate if patients" expectations regarding fampridine, assessed before initiating treatment influenced their clinical response.
Methods: We designed a prospective study from June 2015 to April 2016. We invited all consecutive patients considered for fampridine treatment in our centre to participate. Clinical data was collected and patients completed a questionnaire which included a question about fampridine information sources, a portuguese version of the Stanford Expectations of Treatment Scale (SETS) and the HADS scale to assess depression and anxiety. We analysed the effect of positive expectancy, as well as sex, age, EDSS score, and disease duration in the response at 4 weeks through a logistic regression. Chi square or Fisher analysis were used as apropriate.
Results: Out of 36 patients proposed to fampridine treatment, 32 agreed to participate in our study. 69.7% (23) were female; mean age was 52.5 years, median EDSS was 6. A benefit higher than 20% in T25FW at week 4 was observed in 72.7% (24) of patients. A high positive expectancy on SETS was the only factor associated with benefit at 4 weeks, being associated with a five-fold increase in odds of benefit at 4 weeks (OR= 5.0, 95% CI 1.01-25.57, p=0,049). Fampridine information sources, anxiety and depression scores weren"t related to SETS results.
Conclusions: In our sample, the expectations of patients seemed more relevant than sex, age, EDSS score and duration of disease in patients" response to fampridine after 4 weeks of treatment. It would be interesting to assess with bigger samples if indeed patients" expectations regarding treatment are an important factor in fampridine response.
Disclosure:
Filipa Ladeira has received travel fees from Biogen,Teva, Genzyme
Ana Sofia Correia received an educational sponsorship from Merck Serono, honorarium for advisory role from Novartis, research support and honorarium for lecturing from Biogen Idec and support for scientific meetings from Novartis, Biogen Idec, Teva and Bayer.
Miguel Viana-Baptista has no conflicts of interest